Almirall, S.A. (E2Z.F)
Frankfurt - Frankfurt Delayed price. Currency in EUR
Add to watchlist
At close: 08:07AM CEST
| Previous close | 9.81 |
| Open | 9.81 |
| Bid | 9.80 x 170000 |
| Ask | 9.88 x 170000 |
| Day's range | 9.81 - 9.81 |
| 52-week range | 7.43 - 9.81 |
| Volume | |
| Avg. volume | 1 |
| Market cap | 2.102B |
| Beta (5Y monthly) | 0.38 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | 0.18 (1.88%) |
| Ex-dividend date | 17 May 2024 |
| 1y target est | N/A |
- Investing.com
Almirall's Ebglyss poised for EU approval, challenging Sanofi and Regeneron’s Dupixent
Almirall, the Spanish pharmaceutical company, is on the brink of securing European Union (EU) approval for its IL-13 inhibitor lebrikizumab, marketed as Ebglyss, for atopic dermatitis treatment. The European Medicines Agency's (EMA) human medicines committee has recommended the drug's approval, setting up a challenge to the market-leading Dupixent, produced by Sanofi (NASDAQ:SNY) and Regeneron (NASDAQ:REGN).
© 2024 Yahoo. All rights reserved.